Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY2402234 in Advanced Myeloid Malignancies
NCT03404726Phase 1Terminated
- Sponsor
- Bayer
- Start
- Mar 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of orludodstat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose up to 42 days, Dose Limiting Toxicities up to 42 days and 3 more. Started Mar 2018; status: terminated.
02
Drugs
orludodstat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03404726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404726.